CN-122005754-A - Application of ganoderma lucidum immunomodulatory protein in preparation of product for targeting TK1

Abstract

The invention discloses application of ganoderma lucidum immunomodulatory protein in preparation of a product for targeting TK1, and belongs to the technical field of biological medicines. The protein can be directly combined with a tumor proliferation marker TK1, and the expression level of the TK1 is reduced, so that the proliferation of tumor cells is inhibited. The invention discloses a molecular mechanism of ganoderma lucidum immunomodulatory protein for exerting an anti-tumor effect by targeting TK1 for the first time, and particularly discloses an amino acid site of interaction of ganoderma lucidum immunomodulatory protein and TK 1. Based on the findings, the invention also provides a food, health food or medicine for inhibiting TK1 or tumor, which comprises ganoderma lucidum immunomodulatory protein, and is especially suitable for preventing and treating breast cancer. The invention provides a new direction for the clinical application transformation of ganoderma lucidum immunomodulatory proteins, and has important development value and application prospect.

Inventors

• LI QIZHANG
• Zuo Zanwen
• QIAN XIAOXUAN
• WANG ZIHAN

Assignees

• 淮北师范大学

Dates

Publication Date

20260512

Application Date

20260226

Claims (9)

1. 1. An application of ganoderma lucidum immunomodulatory protein in preparing a product for targeting thymidine kinase 1.
2. 2. Use of a ganoderma lucidum immunomodulatory protein according to claim 1 for the preparation of a product for targeting thymidine kinase 1, wherein the ganoderma lucidum immunomodulatory protein binds to thymidine kinase 1.
3. 3. Use of a ganoderma lucidum immunomodulatory protein according to claim 1 or 2 for the preparation of a product for targeting thymidine kinase 1, wherein the amino acid sequence of the ganoderma lucidum immunomodulatory protein is shown in SEQ ID No. 1.
4. 4. Use of a ganoderma lucidum immunomodulatory protein according to claim 3 for the preparation of a product for targeting thymidine kinase 1, wherein amino acid residues L43, T44, S69 and Q73 of the a chain and amino acid residues N24, R27, D88, Q109 and N111 of the B chain of ganoderma lucidum immunomodulatory protein interact with amino acid residues Q20, R38, R42, Y48, R130, E144, R158 and R186 of TK1, respectively.
5. 5. Use of a ganoderma lucidum immunomodulatory protein according to any of claims 1-4 for the preparation of a product for targeting thymidine kinase 1, wherein the ganoderma lucidum immunomodulatory protein is useful for reducing the expression level of TK 1.
6. 6. A composition for inhibiting thymidine kinase 1, comprising the ganoderma lucidum immunomodulatory protein of any one of claims 1-5.
7. 7. A composition for inhibiting a tumor, comprising the ganoderma lucidum immunomodulatory protein of any of claims 1-5.
8. 8. The composition of claim 7, wherein the composition is a food, a health food, or a pharmaceutical.
9. 9. The composition of claim 7 or 8, wherein the tumor is breast cancer.

Description

Application of ganoderma lucidum immunomodulatory protein in preparation of product for targeting TK1 Technical Field The invention belongs to the technical field of biological medicines, and particularly relates to application of ganoderma lucidum immunomodulatory protein in preparation of a product for targeting TK 1. Background Thymidine kinase 1 (THYMIDINE KINASE, tk1) is a key enzyme in DNA synthesis and damage repair processes, and its activity is closely related to the state of cell proliferation. In normal cells, TK1 activity has cell cycle dependence, and in various malignant tumor cells, TK1 often presents abnormal high expression, so that the TK1 becomes an important tumor proliferation marker and is widely applied to auxiliary diagnosis and prognosis evaluation of cancers such as lung cancer, colorectal cancer, breast cancer, prostate cancer and the like. Studies have shown that TK1 not only provides a substrate for DNA replication, but also plays an important role in repairing DNA damage caused by chemotherapy or radiotherapy by cells. Thus, targeting TK1 to inhibit its function or expression is a potential strategy in the field of tumor therapy. Breast cancer is one of the most common malignant tumors in women worldwide, and its treatment regimen varies from one molecular subtype to another. Although the existing treatment methods (such as surgery, radiotherapy, chemotherapy, endocrine therapy and targeted therapy) have been significantly advanced, the problems of limited curative effect, drug resistance, toxic and side effects and the like still exist for partial subtype (such as Luminal A type) or recurrent metastatic patients. Therefore, the continuous development of novel antitumor drugs or functional products with novel action mechanisms, high efficiency and low toxicity is an important requirement to be solved in clinical urgent need. Ganoderma lucidum has been widely studied as a conventional medicinal fungus, and its extract and active ingredient, wherein ganoderma lucidum immunomodulatory protein (FIP-glu) has been demonstrated to have various biological activities such as immunomodulation and anti-tumor. However, the specific molecular targets and signaling pathways for FIP-glu anti-tumor effects are not yet fully elucidated, and there is especially no evidence of whether they can directly act on the key tumor marker of TK 1. This cognitive gap severely limits further development and clinical application conversion of FIP-glu as a precisely targeted therapeutic. Therefore, the deep molecular mechanism of FIP-glu anti-tumor, especially anti-breast cancer is clarified, the direct acting target point is clarified, and the FIP-glu anti-tumor protein has important significance in developing novel targeted therapeutic drugs, health-care foods or functional foods based on the protein. Disclosure of Invention The invention provides an application of ganoderma lucidum immunomodulatory protein in preparing a product for targeting TK 1. Experiments show for the first time that FIP-glu can be directly combined with TK1 and down-regulate the protein expression, so that the proliferation of tumor cells is inhibited. Based on the new mechanism, the invention provides a food, health-care food or medicine containing FIP-glu for inhibiting TK1 or tumors (such as breast cancer), and provides a new strategy for developing novel anti-tumor products. In one aspect, the invention provides an application of ganoderma lucidum immunomodulatory protein in preparing a product for targeting thymidine kinase 1 (TK 1), and the application adopts the following technical scheme: use of ganoderma lucidum immunomodulatory protein in the preparation of a product for targeting thymidine kinase 1 (TK 1). Preferably, the ganoderma lucidum immunomodulatory protein binds to thymidine kinase 1 (TK 1). Preferably, the amino acid sequence of the ganoderma lucidum immunomodulatory protein is shown as SEQ ID NO. 1. Preferably, amino acid residues L43, T44, S69 and Q73 of the A chain and amino acid residues N24, R27, D88, Q109 and N111 of the B chain of the ganoderma lucidum immunoregulatory protein interact with amino acid residues Q20, R38, R42, Y48, R130, E144, R158 and R186 of TK1, respectively. Preferably, ganoderma lucidum immunomodulatory proteins may be used to reduce the expression level of TK 1. The invention also provides a composition for inhibiting thymidine kinase 1 (TK 1), which comprises the ganoderma lucidum immunomodulatory protein. The invention also provides a composition for inhibiting tumor, which comprises the ganoderma lucidum immunomodulatory protein. Preferably, the composition is a food, a health food or a medicament. Preferably, the tumor is breast cancer. In summary, the beneficial effects of the invention are as follows: The invention discloses a molecular mechanism of directly targeting and combining with thymidine kinase 1 (TK 1) and down regulating expression of ganoderma lucidum immunomodulatory